S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
OTCMKTS:CNTMF

Cansortium Stock Forecast, Price & News

$0.68
-0.04 (-5.56 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.63
Now: $0.68
$0.72
50-Day Range
$0.66
MA: $0.75
$0.83
52-Week Range
$0.05
Now: $0.68
$0.99
Volume595,902 shs
Average Volume486,491 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. It operates cultivation, processing, and dispensary facilities in Florida and Texas; and a dispensary license in Pennsylvania. The company offers its products in the form of oral drops, capsules, suppositories, topicals, syringes, dried flowers, prerolls, and cartridges. It markets its products under the Fluent brand name. As of December 21, 2020, it operated 24 dispensaries. Cansortium Inc. was founded in 2015 and is headquartered in Miami, Florida.

Headlines

Clarification of Smith Group Share Ownership
February 2, 2021 |  finance.yahoo.com
Acquisition of Securities of Cansortium, Inc.
January 26, 2021 |  finance.yahoo.com
Cansortium Announces Resignation of Marcos Pedreira
December 21, 2020 |  finance.yahoo.com
Cansortium beats on revenue, reiterates FY20 outlook
November 23, 2020 |  seekingalpha.com
Cansortium Inc. Reports 2020 Third Quarter Financial Results
November 23, 2020 |  finance.yahoo.com
Cansortium has a new CEO
September 29, 2020 |  seekingalpha.com
Cansortium Inc. Reports Second Quarter Financial Results
August 26, 2020 |  finance.yahoo.com
Cansortium Announces Amendment to Convertible Notes
August 17, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CNTMF
CUSIPN/A
CIKN/A
Phone305-902-2720
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

952nd out of 1,968 stocks

Drug Manufacturers - Specialty & Generic Industry

18th out of 61 stocks

Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.68
-0.04 (-5.56 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNTMF News and Ratings via Email

Sign-up to receive the latest news and ratings for CNTMF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cansortium (OTCMKTS:CNTMF) Frequently Asked Questions

Is Cansortium a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cansortium in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cansortium stock.
View analyst ratings for Cansortium
or view top-rated stocks.

What stocks does MarketBeat like better than Cansortium?

Wall Street analysts have given Cansortium a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cansortium wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cansortium?

Cansortium saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 1,400 shares, a drop of 90.3% from the January 28th total of 14,500 shares. Based on an average daily trading volume, of 1,032,600 shares, the short-interest ratio is currently 0.0 days.
View Cansortium's Short Interest
.

How has Cansortium's stock price been impacted by COVID-19?

Cansortium's stock was trading at $0.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNTMF shares have increased by 209.1% and is now trading at $0.68.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CNTMF?

1 analysts have issued 1 year price targets for Cansortium's shares. Their forecasts range from $1.20 to $1.20. On average, they expect Cansortium's share price to reach $1.20 in the next year. This suggests a possible upside of 76.5% from the stock's current price.
View analysts' price targets for Cansortium
or view top-rated stocks among Wall Street analysts.

Who are Cansortium's key executives?

Cansortium's management team includes the following people:
  • Mr. Neal A. Hochberg, Exec. Chairman
  • Mr. Henry Batievsky, Co-Founder, Chief Production Officer & Interim CFO
  • Mr. Todd A. Buchman, Chief Legal Officer & Corp. Sec.
  • Mr. Jeffrey Reath, Consultant
  • Mr. Robert Beasley, CEO & Director
  • Dr. Jennifer McCafferty-Fernandez, Chief Science Officer
  • Ms. Samantha Hymes, Exec. VP of Operations

Who are some of Cansortium's key competitors?

What is Cansortium's stock symbol?

Cansortium trades on the OTCMKTS under the ticker symbol "CNTMF."

How do I buy shares of Cansortium?

Shares of CNTMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cansortium's stock price today?

One share of CNTMF stock can currently be purchased for approximately $0.68.

What is Cansortium's official website?

The official website for Cansortium is www.cansortium.com.

How can I contact Cansortium?

The company can be reached via phone at 305-902-2720.


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.